From the outset the company has a combination of rare strategic, commercial and technology advantages:

All PhenoCure technologies are ready for commercialisation
EVIDENCE: PhenoCure has initiated and progressed discussions with the top 10 Pharmaceutical companies and broadly achieved a high degree of interest.

PhenoCure has a drug compound that is applicable for colon cancer
EVIDENCE: Colon cancer tumour cells were selectively and rapidly killed by PhenoCure’s lead compound CC1. Other drugs for other cancers are being developed.

PhenoCure’s PFR technology can be used for discovering drugs for most other single gene disorders
EVIDENCE: CC1, an effective anti-cancer compound was discovered using this proprietary technology.

PhenoCure’s Foldase and assoc tech technologies can shorten and enhance the drug discovery process
EVIDENCE: Proteins can have activity levels 100 fold in excess of previous methods.
Time consuming and expensive purification and refolding steps are simplified and removed, respectively.

PhenoCure’s Foldase and associated technologies can resurrect previously abandoned therapeutic projects
EVIDENCE: Foldase technologies can produce functional proteins from previously inactive proteins

PhenoCure's PFR technologies are a superior alternative to gene therapy
EVIDENCE: PFR drugs can be safely administered as a pill.

There is no known competition for the company’s technologies.